Illumina, Inc. (ILMN) Stock Analysis

Illumina’s principal competitive advantage lies in its dominant position in short-read next-generation sequencing (NGS), underpinned by a global installed base exceeding 20,000 instruments and a consumables-driven business model. In 2025, over 70% of sequencing revenue derived from proprietary reagents and flow cells, with gross margins on consumables typically in the 70–75% range. This recurring revenue stream is reinforced by high customer switching costs: laboratories invest heavily in workflow validation, staff training, and regulatory approvals, making transitions to rival platforms costly and disruptive.

Technological leadership is another core strength. Illumina’s sequencing-by-synthesis (SBS) chemistry, now in its XLEAP-SBS iteration, remains the industry benchmark for accuracy and throughput. The NovaSeq X platform, for example, can deliver over 20,000 whole genomes per year at a cost below $200 per genome, a figure competitors have yet to match at scale. The company’s DRAGEN bioinformatics suite and integrated software ecosystem further lock in customers by streamlining data analysis and compliance.

Intellectual property is a significant barrier to entry, with Illumina holding more than 9,000 active patents globally. While rivals such as Thermo Fisher, Pacific Biosciences, Oxford Nanopore, and BGI have made inroads—especially in long-read, low-cost, or regional markets—none match Illumina’s combination of scale, regulatory trust, and end-to-end workflow integration.